시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 레베르 유전성 시신경병증(LHON) 치료 시장 보고서(2025년)
Leber Hereditary Optic Neuropathy Treatment Global Market Report 2025
상품코드 : 1751037
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,521,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,426,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,330,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

레베르 유전성 시신경병증(LHON) 치료 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안 예상되는 성장은 혁신적인 치료법과 개입에 대한 수요 증가, 전문 진단 서비스의 필요성 증가, 시신경 질환에 대한 인식 향상 및 조기 발견, LHON의 신규 치료에 대한 관심 증가, 제품 설계와 품질 개선에 있어서의 지속적인 진보에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 표적 치료의 개발, 유전자 검사 기술의 진보, 외과적·약리학적 치료법의 진보, 유전자 치료 기술의 혁신, 유전자 치료 응용의 광범위한 확대 등이 있습니다.

녹내장과 시신경염의 이환율 증가는 향후 몇 년간의 레베르 유전성 시신경병증(LHON) 치료 시장의 성장에 크게 기여할 것으로 예측됩니다. 자신의 면역 질환과 관련된 염증과 관련이 있으며, 모두 시력 저하로 이어질 수 있습니다. 전 세계 인구가 계속 고령화됨에 따라 안압 상승으로 인한 시신경 손상을 특징으로 하는 녹내장 발병 위험이 현저히 증가하고 있습니다. 녹내장과 시신경염은 모두 시신경 변성을 동반하여 LHON과 유사한 질환입니다. 2024년 10월 미국 질병 예방관리센터는 현재 300만명 이상의 미국인이 녹내장을 앓고 있으며, 고령화에 의해 2050년까지 그 수는 2배인 630만명이 될 것으로 예상된다고 보고했습니다.

표적치료의 진보도 시각관련질환의 유전자치료에 있어서 기술 혁신을 촉진하는데 중요한 역할을 하고 있습니다. ND4 등의 결함이 있는 미토콘드리아 유전자의 기능적 카피를 제공함으로써 시력을 회복시키도록 설계되어 있습니다. Neurophth Therapeutics는 중국과 미국에서 ND1-LHON 치료의 I/II 상 임상시험을 시작했습니다. 첫 번째 환자에게 투여하는 것은 회사의 세계 개발 전략에서 중요한 이정표이며, 회사는 계속 환자 모집을 가속화하고 다른 희귀질환과 암멧 의료 요구에 대한 추가 유전자 치료 솔루션을 탐구하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Leber hereditary optic neuropathy (LHON) treatment involves medical strategies designed to manage or alleviate the effects of LHON, a rare genetic condition that leads to sudden vision loss, most often in young adults. This disorder is caused by mutations in mitochondrial DNA, which result in degeneration of the optic nerve due to impaired function of retinal ganglion cells, leading to significant vision impairment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Primary treatment options for LHON include medication, stem cell therapy, gene therapy, and genetic counseling. Medications help manage symptoms by addressing underlying causes and may be administered in forms such as tablets or injections to reduce inflammation, support nerve health, and treat conditions associated with LHON. These treatments are delivered through various routes, including intramuscular, oral, and others. Diagnosis is made using a range of methods such as molecular genetic testing, magnetic resonance imaging (MRI), and blood tests. Treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a variety of end-users, including clinics, hospitals, and other healthcare facilities.

The leber hereditary optic neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides leber hereditary optic neuropathy treatment market statistics, including the leber hereditary optic neuropathy treatment industry global market size, regional shares, competitors with the leber hereditary optic neuropathy treatment market share, detailed leber hereditary optic neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the leber hereditary optic neuropathy treatment industry. This leber hereditary optic neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leber hereditary optic neuropathy treatment market size has grown strongly in recent years. It will grow from $0.36 billion in 2024 to $0.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of Leber hereditary optic neuropathy, an aging population, an increasing incidence of diabetes, growing demand for cell-free DNA in maternal plasma testing, and increased investment in the healthcare sector.

The leber hereditary optic neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $0.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to the rising demand for innovative therapies and interventions, increasing need for specialized diagnostic services, greater awareness and early detection of optic neuropathies, growing interest in novel treatments for LHON, and ongoing advancements in product design and quality improvement. Key trends expected during this period include the development of targeted therapies, progress in genetic testing technologies, advancements in both surgical and pharmacological treatment options, innovations in gene therapy techniques, and the broader expansion of gene therapy applications.

The increasing incidence of glaucomas and optic neuritis is expected to contribute significantly to the growth of the Leber hereditary optic neuropathy (LHON) treatment market in the coming years. Glaucoma and optic neuritis are eye disorders that result in damage to the optic nerve, with glaucoma commonly caused by elevated intraocular pressure, and optic neuritis typically associated with inflammation linked to autoimmune conditions, both potentially leading to vision loss. The growing occurrence of these conditions is largely attributed to an aging population and advancements in diagnostic technologies. As the global population continues to age, the risk of developing glaucoma characterized by optic nerve damage due to increased intraocular pressure rises markedly. Both glaucoma and optic neuritis involve optic nerve degeneration, a condition similar to LHON. With the rising prevalence of these disorders, research and awareness efforts are becoming more focused on therapies targeting optic nerve damage, which also aids in advancing treatment options for LHON. For example, in October 2024, the Centers for Disease Control and Prevention reported that over 3 million Americans currently suffer from glaucoma, a number expected to double to 6.3 million by 2050 due to the aging population. This trend is contributing to the growing demand for LHON treatment solutions.

Advancements in targeted therapies are also playing a key role in driving innovation in the genetic treatment of vision-related disorders. Leading companies in the LHON treatment market are prioritizing the development of cutting-edge treatments, including gene therapy clinical trials, with the aim of enhancing therapeutic efficacy, restoring mitochondrial function, and addressing the genetic basis of LHON. These gene therapy initiatives are designed to restore vision by delivering functional copies of defective mitochondrial genes, such as ND4. These treatments undergo rigorous phases, from preclinical studies through to phase 1, 2, and 3 clinical trials, before regulatory approval can be granted. For instance, in August 2023, Neurophth Therapeutics, a gene therapy company based in China, launched a Phase I/II clinical trial for ND1-LHON treatment in China and the United States. This trial, which received approval from both the U.S. FDA and China's NMPA, aims to assess the safety, tolerability, and effectiveness of its NFS-02 therapy. The dosing of the first patient marked a significant milestone in the company's global development strategy, as it continues to accelerate patient recruitment and explore further gene therapy solutions for other rare and unmet medical needs.

In July 2023, Chiesi Farmaceutici S.p.A., an Italy-based company specializing in research-driven healthcare solutions, acquired the Raxone/idebenone business from Santhera Pharmaceuticals for an undisclosed sum. This acquisition is intended to enhance Chiesi's rare disease portfolio and reinforce its position in the treatment of Leber hereditary optic neuropathy (LHON). Santhera Pharmaceuticals, based in Switzerland, focuses on developing treatments for LHON.

Major players in the leber hereditary optic neuropathy treatment market are UPMC, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic Foundation, The Children's Hospital of Philadelphia, Chiesi Farmaceutici S.p.A., Medicover Hospitals, Harvard Medical School, BridgeBio Pharma Inc., Neurophth Therapeutics Co. Ltd., PreventionGenetics, Stealth BioTherapeutics Corp., Genethon, Reneo Pharmaceuticals Inc., GenSight Biologics S.A., Eye Stem Cell Center, Khondrion B.V., Ixchel Pharma Inc., Abliva AB, Mitotech S.A.

North America was the largest region in the leber hereditary optic neuropathy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber hereditary optic neuropathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leber hereditary optic neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leber hereditary optic neuropathy treatment market consists of revenues earned by entities providing services such as mitochondrial support therapies, diagnostic testing, and vision rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber hereditary optic neuropathy (LHON) treatment market also includes sales of antioxidants and supportive care medications aimed at managing vision loss and disease progression. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leber Hereditary Optic Neuropathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leber hereditary optic neuropathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for leber hereditary optic neuropathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber hereditary optic neuropathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Leber Hereditary Optic Neuropathy Treatment Market Characteristics

3. Leber Hereditary Optic Neuropathy Treatment Market Trends And Strategies

4. Leber Hereditary Optic Neuropathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Leber Hereditary Optic Neuropathy Treatment Growth Analysis And Strategic Analysis Framework

6. Leber Hereditary Optic Neuropathy Treatment Market Segmentation

7. Leber Hereditary Optic Neuropathy Treatment Market Regional And Country Analysis

8. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market

9. China Leber Hereditary Optic Neuropathy Treatment Market

10. India Leber Hereditary Optic Neuropathy Treatment Market

11. Japan Leber Hereditary Optic Neuropathy Treatment Market

12. Australia Leber Hereditary Optic Neuropathy Treatment Market

13. Indonesia Leber Hereditary Optic Neuropathy Treatment Market

14. South Korea Leber Hereditary Optic Neuropathy Treatment Market

15. Western Europe Leber Hereditary Optic Neuropathy Treatment Market

16. UK Leber Hereditary Optic Neuropathy Treatment Market

17. Germany Leber Hereditary Optic Neuropathy Treatment Market

18. France Leber Hereditary Optic Neuropathy Treatment Market

19. Italy Leber Hereditary Optic Neuropathy Treatment Market

20. Spain Leber Hereditary Optic Neuropathy Treatment Market

21. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market

22. Russia Leber Hereditary Optic Neuropathy Treatment Market

23. North America Leber Hereditary Optic Neuropathy Treatment Market

24. USA Leber Hereditary Optic Neuropathy Treatment Market

25. Canada Leber Hereditary Optic Neuropathy Treatment Market

26. South America Leber Hereditary Optic Neuropathy Treatment Market

27. Brazil Leber Hereditary Optic Neuropathy Treatment Market

28. Middle East Leber Hereditary Optic Neuropathy Treatment Market

29. Africa Leber Hereditary Optic Neuropathy Treatment Market

30. Leber Hereditary Optic Neuropathy Treatment Market Competitive Landscape And Company Profiles

31. Leber Hereditary Optic Neuropathy Treatment Market Other Major And Innovative Companies

32. Global Leber Hereditary Optic Neuropathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leber Hereditary Optic Neuropathy Treatment Market

34. Recent Developments In The Leber Hereditary Optic Neuropathy Treatment Market

35. Leber Hereditary Optic Neuropathy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기